Hims & Hers Health, Inc. (HIMS)
NEUTRALFundamental
32
Kurs
$31.64
Marktkapitalisierung
$7.88B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Hims & Hers runs a direct-to-consumer telehealth platform that connects patients with licensed providers who can prescribe treatments for conditions such as weight loss, sexual health, dermatology, hair loss and mental health. Patients fill out an online questionnaire, a provider reviews it and, where appropriate, writes a prescription that is fulfilled by the company's own or partner pharmacies and shipped directly to the customer, without an in-person doctor visit.
Wie das Geld verdient wird
Most revenue comes from recurring monthly subscriptions that bundle a treatment plan, medication and provider access into a single price, rather than from one-off purchases. A smaller share is wholesale sales of over-the-counter products. Pricing ranges from roughly $20-40 a month for basic plans to well over $100 for specialty treatments such as compounded weight-loss drugs, and the company reports most subscribers stay active well beyond the first few months.
Umsatz nach Segment
The core market: nearly all subscribers and revenue, across every treatment category the company offers.
International markets including the UK, Canada and continental Europe, growing much faster than the US but still a small share of the total.
Wettbewerbsvorteil
Kein erkennbarer Vorteil · KeinerThe company holds no patents on the medications it prescribes and its questionnaire-and-prescription model is replicable by other telehealth platforms, several of which already compete for the same customers. Its advantage today rests on brand recognition built through heavy advertising and on its pharmacy network, neither of which is hard for a well-funded rival to copy.
Was die Nachfrage antreibt
Mäßig zyklischTreatments are paid out of pocket rather than through insurance, so demand has some sensitivity to household budgets, but much of it — ongoing prescriptions for chronic conditions like weight management or hair loss — behaves more like a recurring habit than a discretionary purchase once a subscriber is established.
Wichtigste Risiken
- FDA scrutiny of compounded-drug marketing — The company states that promotion of the compounded drugs made by its pharmacies is subject to FDA regulation, that misleading promotional claims can lead to a drug being deemed misbranded, and that enforcement can include warning letters or, in extreme cases, criminal prosecution.
- Continuity of compounded GLP-1 offerings — The company warns it cannot guarantee it will keep offering compounded weight-loss products in the same way or at all, citing supply chain, intellectual property and regulatory factors outside its control, after the FDA narrowed the conditions under which such compounding is allowed.
- State-by-state telehealth regulation — Providers on the platform must generally hold a license in the state where the patient is located, and telehealth regulation is still developing and applied unevenly across states, adding compliance complexity as the company grows.
Kundenkonzentration
Revenue is spread across more than 2.5 million individual subscribers rather than a small number of large customers, so single-customer concentration is not a relevant risk here.
Die Argumente dafür
Buyers argue that the subscription model and expanding treatment categories give the company a large and growing base of recurring, cash-pay revenue, that international expansion adds a long growth runway, and that the regulatory pressure on compounded GLP-1s pushes the company toward higher-margin branded and proprietary offerings rather than ending the business.
Die Argumente dagegen
Sellers fear that a large share of recent growth came from compounded weight-loss drugs now under direct FDA and legal pressure, that the questionnaire-based model is easy for well-funded competitors to replicate, and that rising marketing costs to keep acquiring subscribers could compress margins even as revenue keeps growing.
Written by the editors, published on 18. August 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$2.58B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-142M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$57M
Gesamtes Eigenkapital
$541M
Gesamtverbindlichkeiten
$1.61B
Current Ratio
0.93
Zinsdeckungsgrad
-
Schulden/EBITDA
9.66
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$30.85
Aktueller Kurs
$31.64
Sicherheitsmarge
-2.6%
Innerer-Wert-Spanne
$29.30 - $32.39
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
66.24
ROE
23.7%
P/B-Verhältnis
-
P/FCF
0.00
Bruttomarge
68.4%
ROIC
-5.7%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-5.7%
WACC
14.6%
ROIC − WACC
-20.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (6)
- EPS shows upward trend
- Price CAGR 19.16%
- Gross Margin 68.4%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
Nicht bestanden (13)
- ROIC -5.7%
- Operating Margin -6.0%
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Unknown)
- ROE -2.5%
- Analyst Consensus 41% Buy
- Earnings Surprise avg -275.4%
- Share Dilution 5.8%
- Net Margin Trend -5.5% vs 9.6%
- Piotroski F-Score 4/9
Nicht verfügbar (8)
- P/FCF 0.00
- P/B Ratio NaN
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Andrew Dudum | Co-Founder, Chairman & CEO | 37 |
| Mr. Oluyemi Okupe | Chief Financial Officer | 39 |
| Mr. Mike Chi | Chief Operating Officer | 45 |
| Mr. Mohamed ElShenawy | Chief Technology Officer | 50 |
| Ms. Soleil Teubner Boughton J.D. | Chief Legal Officer & Corporate Secretary | 47 |
| Dr. Patrick Carroll M.D. | Global Chief Medical Officer | 67 |
| Ms. Deborah M. Autor J.D. | Chief Policy Officer & Director | 58 |
| Ms. Irene A. Becklund | Chief Accounting Officer | 41 |
| Mr. William James Newby | Senior Director of Investor Relations | - |
| Ms. Kathryn H. Beiser B.A., M.S. | Chief Communications Officer | - |
Prüfungsrisiko
2
Vorstandsrisiko
7
Vergütungsrisiko
7
Aktionärsrechterisiko
10
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for HIMS, sourced from Markets Gazette.
- 15d agoNEGATIVEHims & Hers Lowers Profit Forecast, Shares Drop
Hims & Hers Health Inc. has seen its shares decline following a downward revision to its full-year adjusted EBITDA forecast. The telehealth company has lowered the upper limit of its guidance, signaling potential headwinds or a more challenging operating environment than previously anticipated. This adjustment raises concerns among investors about the company's profitability trajectory and its ability to meet future financial targets. The market's reaction underscores the sensitivity to forward-looking financial projections, particularly for growth-oriented companies in the healthcare technology sector.
- 6/18/2026POSITIVEHims & Hers Stock Jumps After Barclays Raises Price Target
Hims & Hers Health Inc. (NYSE: HIMS) experienced a significant stock price increase following Barclays' reaffirmation of a positive outlook. The investment bank raised its price target for HIMS from $29 to $39, signaling strong conviction in the company's future performance. This upward revision suggests that analysts at Barclays see substantial untapped value in the company, potentially driven by factors such as market growth, competitive positioning, or upcoming product launches. Investors are likely to interpret this upgraded target as a strong buy signal, potentially leading to further price appreciation.
- 6/12/2026NEGATIVEHims & Hers Health Stock Slides Friday: What's Going On?
Hims & Hers Health Inc. saw its stock price decline on Friday, giving back recent gains. This downturn follows the announcement of a new Chief Marketing Officer (CMO) appointment. While the company's stock breadth remains constructive, the market appears to be reacting negatively to the news, leading to a slide in its share price. Investors are likely digesting the implications of the new CMO's strategy and its potential impact on future growth and profitability.
- 5/15/2026POSITIVE$1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth This Much Today
An investment of $1,000 in Hims & Hers Health Inc. five years ago would have yielded a significant return, illustrating the company's strong growth trajectory. While specific figures are not provided in the title, the implication of a substantial increase in value suggests robust performance and market acceptance. This historical performance data is crucial for investors assessing the company's long-term potential and its ability to generate shareholder value. The positive trend indicates successful business operations and potentially increasing market share in the telehealth and wellness sector.
- 5/12/2026NEGATIVEHims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts
Hims & Hers Health Inc. experienced a significant share price decline following its Q1 earnings report, which presented a mixed financial picture. While the company elevated its 2026 revenue projections, it simultaneously reduced its EBITDA outlook by $25 million. This downward revision in profitability guidance, coupled with what analysts describe as 'noise' surrounding its weight-loss products, has overshadowed the positive revenue forecast. Investors are likely weighing the near-term profitability concerns against the longer-term revenue potential, leading to a cautious sentiment.
- 5/11/2026NEGATIVEWhy Hims & Hers Health Are Falling Monday
Hims & Hers Health Inc. reported its Q1 results, revealing a miss on revenue estimates despite an increase in subscriber numbers. The company's stock experienced a significant decline, falling over 9% in after-hours trading following the announcement. This revenue shortfall, even with subscriber growth, suggests potential challenges in monetization or increased customer acquisition costs that are impacting the top line. Investors will be closely watching for management's commentary on the revenue miss and future strategies to address this during the earnings call.
- 4/16/2026POSITIVEWhy Is Hims & Hers Stock Soaring After FDA's Announcment?
Hims & Hers Health, Inc. (HIMS) shares experienced a significant surge following the U.S. Food and Drug Administration's (FDA) announcement regarding potential easing of regulations for peptide therapies. This regulatory shift is anticipated to unlock substantial new revenue streams for the company, which specializes in telehealth services and prescription treatments. The revised outlook suggests a more favorable environment for Hims & Hers to expand its offerings in areas utilizing peptide-based treatments, potentially boosting its market position and investor valuation.
- 4/15/2026NEUTRALHere's How Much $1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth Today
An investment of $1000 in Hims & Hers Health Inc. (HIMS) five years ago would have yielded approximately $2,100 today, representing a 110% return. This analysis tracks the stock's performance over the past half-decade, highlighting its growth trajectory. While past performance is not indicative of future results, this historical data provides context for potential investors evaluating the company's long-term value proposition and market position in the telehealth and wellness sector.
via Markets Gazette